Stifel downgraded Surgery Partners (NASDAQ: SGRY) from Hold to Sell with a price target of $17.00 (from $21.00).

Analyst Chris Vanacore expects NT pressure on the product mix and sees operating expenses constraining growth. The analyst also discussed his disappointment with guidance and believes investors will share the same sentiment.

For an analyst ratings summary and ratings history on Surgery Partners click here. For more ratings news on Surgery Partners click here.

Shares of Surgery Partners closed at $19.15 yesterday.